← Back to Search
Survivin, Versatile Modulation Of Cell Division And Apoptosis In Cancer
Published 2003 · Biology, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Survivin is a member of the inhibitor of apoptosis (IAP) gene family that has attracted attention from several viewpoints of basic and translational research. Its cell cycle-regulated expression at mitosis and association with the mitotic apparatus have been of interest to cell biologists studying faithful segregation of sister chromatids and timely separation of daughter cells. Investigators interested in mechanisms of apoptosis have found survivin an evolving challenge: while survivin inhibits apoptosis in vitro and in vivo, this pathway may be more selective as compared to cytoprotection mediated by other IAPs. Finally, basic and translational researchers in cancer biology have converged on survivin as a pivotal cancer gene, not simply for its sharp expression in tumors and not in normal tissues, but also for the potential exploitation of this pathway in cancer diagnosis and therapy. The objective of the present contribution is to line up current evidence and emerging concepts on the multifaceted functions of survivin in cell death and cell division, and how this pathway is being pursued for novel cancer therapeutic strategies.
This paper references
G. G. Stokes (1890)
AC Tose (1993)
G Ambrosini (1997)
Control of apoptosis and mitotic spindle checkpoint by survivin
F. Li (1998)
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.
N. Gray (1998)
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma
C. Adida (1998)
D Yu (1998)
C Adida (1998)
Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division.
A. Uren (1999)
Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.
H. Swana (1999)
Transcriptional analysis of human survivin gene expression.
F. Li (1999)
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma.
D. Grossman (1999)
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.
J. Tran (1999)
Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation.
K. Kobayashi (1999)
Y Saitoh (1999)
J Tran (1999)
HS Swana (1999)
F Li (1999)
F Li (1999)
K Kobayashi (1999)
W Zhou (1999)
AG Fraser (1999)
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin.
D. S. O'Connor (2000)
Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition
C. Du (2000)
Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth.
J. Chen (2000)
Expression of the antiapoptosis gene,Survivin, predicts death from recurrent colorectal carcinoma
A. Sarela (2000)
Deterin, a New Inhibitor of Apoptosis from Drosophila melanogaster *
G. Jones (2000)
High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
A. Islam (2000)
Structural basis for phosphoserine-proline recognition by group IV WW domains
M. Verdecia (2000)
Expression and prognostic significance of survivin in de novo acute myeloid leukaemia
C. Adida (2000)
Human Survivin Is a Kinetochore-Associated Passenger Protein
D. Skoufias (2000)
The Hallmarks of Cancer
D. Hanahan (2000)
Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death
A. Suzuki (2000)
Control of apoptosis during angiogenesis by survivin expression in endothelial cells.
D. S. O'Connor (2000)
Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway*
A. Papapetropoulos (2000)
STAT proteins: novel molecular targets for cancer drug discovery
J. Turkson (2000)
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions.
E. Conway (2000)
Survivin does not inhibit caspase-3 activity.
D. Banks (2000)
K Tanaka (2000)
F Khuri (2000)
C Badie (2000)
AG Uren (2000)
C Adida (2000)
SW Muchmore (2000)
L Chantalat (2000)
EK Speliotes (2000)
MA Verdecia (2000)
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53.
D. Grossman (2001)
Participation of Survivin in mitotic and apoptotic activities of normal and tumor‐derived cells *
X. Jiang (2001)
Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1.
Y. Shen (2001)
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting.
M. Mesri (2001)
Proliferation, cell cycle and apoptosis in cancer
G. Evan (2001)
Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy.
J. Kanwar (2001)
Inhibition of melanoma tumor growth in vivo by survivin targeting.
D. Grossman (2001)
Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis.
S. Fukuda (2001)
Survivin inhibition induces human neural tumor cell death through caspase‐independent and ‐dependent pathways
S. L. Shankar (2001)
Aberrant expression of caspase cascade regulatory genes in adult T‐cell leukaemia: survivin is an important determinant for prognosis
S. Kamihira (2001)
An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7.
S. Shin (2001)
Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors
Kimihiko Satoh (2001)
Livin, a Novel Inhibitor of Apoptosis Protein Family Member*
G. M. Kasof (2001)
Cytokine-regulated expression of survivin in myeloid leukemia.
B. Carter (2001)
Y Shen (2001)
A Yagihashi (2001)
D Grossman (2001)
H Yoshida (2001)
SP Wheatley (2001)
J Kato (2001)
R Gianani (2001)
M Mesri (2001)
K Mahboubi (2001)
S Kamihira (2001)
A p34(cdc2) survival checkpoint in cancer.
D. S. O'Connor (2002)
Quantitatively determined survivin expression levels are of prognostic value in human gliomas.
A. Chakravarti (2002)
Gene expression profiling predicts clinical outcome of breast cancer
L. J. Veer (2002)
Apoptosis: IAP proteins: blocking the road to death's door
G. Salvesen (2002)
DNA Damage Induces a Novel p53-Survivin Signaling Pathway Regulating Cell Cycle and Apoptosis in Acute Lymphoblastic Leukemia Cells
Muxiang Zhou (2002)
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway
A. Mirza (2002)
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
G. Schwartz (2002)
Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways.
E. Conway (2002)
Activation of cancer-specific gene expression by the survivin promoter.
R. Bao (2002)
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
J. Tran (2002)
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53*
W. H. Hoffman (2002)
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer
N. Zaffaroni (2002)
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
M. Wetering (2002)
Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin–cyclin B link
F. Kuttler (2002)
survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma
M. Ikeguchi (2002)
The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells.
S. Fukuda (2002)
Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma
P. Würl (2002)
MH Andersen (2002)
T Yamamoto (2002)
CA Koch (2002)
JB Shannon (2002)
MA Bolton (2002)
R Harfouche (2002)
J Tran (2002)
JA Rodriguez (2002)
GS Salvesen (2002)
C Xia (2002)
Sausville EA. (2002)
CR Murphy (2002)
Y Hirohashi (2002)
Y. Shi (2002)
M Ikeguchi (2002)
M Ikeguchi (2002)
Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma
P. Grabowski (2003)
Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
J. Zhang (2003)
Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma.
Y. Aoki (2003)
Expression of survivin in astrocytic tumors
Y. Kajiwara (2003)
Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
D. Hausladen (2003)
Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression.
M. Pennati (2003)
Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
A. Gradilone (2003)
Survivin Enhances Aurora-B Kinase Activity and Localizes Aurora-B in Human Cells*
J. Chen (2003)
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
S. M. Schmidt (2003)
P Grabowski (2003)
JY Zhang (2003)
A Badran (2003)
Altieri DC. (2003)
NS Williams (2003)
This paper is referenced by
Efficient Stable Cell Line Generation of Survivin as an In Vitro Model for Specific Functional Analysis in Apoptosis and Drug Screening
Rashid Houshdarpour (2021)
The prognostic significance of survivin expression in patients with HNSCC: a systematic review and meta-analysis
Liu-Qing Zhou (2021)
PLK1-mediated S369 phosphorylation of RIPK3 during G2 and M phases enables its ripoptosome incorporation and activity
Kartik Gupta (2021)
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis
J. Carlos (2021)
Development of Multi-Scale X-ray Fluorescence Tomography for Examination of Nanocomposite-Treated Biological Samples
Si Chen (2021)
Genetic variants and risk of thyroid cancer among Iranian patients
Mohammad Jamshidi (2021)
Title: The prognostic signi cance of survivin expression in patientswith HNSCC: a systematic review and meta-analysis
Liu-Qing Zhou (2021)
Endometriosis and autoimmunity: Can autoantibodies be used as a non-invasive early diagnostic tool?
H. Greenbaum (2021)
Promising Biomarkers in Renal Cell Carcinoma
J. Kapoor (2021)
Phenylboronic acid-functionalized polyaminoglycoside as an effective CRISPR/Cas9 delivery system
Meiyu Shao (2021)
Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma.
Jing-Jun Nie (2021)
Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer
T. Bos (2021)
Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells
P. Otevřelová (2021)
Survivin and Caspase-3 Cannot Predict Recurrence for Urinary Bladder Carcinoma
Vivian G. D. Rouston (2021)
Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression
A. Stavropoulos (2020)
Identification of nine key genes by bioinformatics analysis for predicting poor prognosis in smoking-induced lung adenocarcinoma
Chuanli Ren (2020)
Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients
L. León-Mateos (2020)
Diagnostic accuracy of urinary survivin mRNA expression detected by RT-PCR compared with urine cytology in the detection of bladder cancer: A meta-analysis of diagnostic test accuracy in head-to-head studies
Liang Fu (2020)
Immunohistochemical expression of insulin-like growth factor-1Ec in primary endometrial carcinoma: Association with PTEN, p53 and survivin expression
A. Stavropoulos (2020)
Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.
Shi-He Liu (2020)
USP47 promotes apoptosis in rat myocardial cells after ischemia/reperfusion injury via NF‐κB activation
Yu Hu (2020)
Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex
Wan-xia Fang (2020)
Unraveling novel survivin mRNA transcripts in cancer cells using an in-house developed targeted high-throughput sequencing approach.
Panagiotis G Adamopoulos (2020)
Smartphone-assisted detection of nucleic acids by light-harvesting FRET-based nanoprobe.
Caterina Severi (2020)
TRAIL therapy and prospective developments for cancer treatment.
Bindu Thapa (2020)
Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines
Samarwadee Plianwong (2020)
Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
K. Kang (2020)
Survivin and Telomerase as Radiotherapeutic Response Predictors of Subjects with Stage IIIB Cervical Squamous Cell Carcinoma
F. Kusuma (2020)
Vitamin D3 (1,25(OH)2D3) ile İşlenmiş HL-60 Hücrelerindeki Gen Anlatımının Zamana Karşı Değişiminin Q-RT-PCR ile Analizi
A. Kanli (2020)
A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma
Yu Qi (2020)
Poly ( amido-amine ) Dendrimers-Based Nanomedicine for Combination Therapy with siRNA and Chemotherapeutics to Overcome Multidrug Resistance in Cancer
Jiayi Pan (2020)
Monocyte chemoattractant protein-1, macrophage colony stimulating factor, survivin, and tissue inhibitor of matrix metalloproteinases-2 in analysis of damage and repair related to pediatric chronic kidney injury.
K. Musiał (2020)See more